Written and maintained by CASRAI Editorial Board
Published
On this page
A hERG assay is an in vitro electrophysiological or biochemical safety screening procedure used during nonclinical drug development to measure whether a candidate pharmaceutical compound inhibits the human Ether-à-go-go-Related Gene (hERG, Kv11.1) potassium channel. Because hERG mediates the rapid delayed rectifier potassium current (IKr) critical for cardiac ventricular repolarization, unintended pharmacological block of this ion channel delays cardiac action potential repolarization, prolongs the electrocardiographic QT interval, and increases the risk of fatal ventricular tachyarrhythmias, particularly Torsades de Pointes (TdP). Under the International Council for Harmonisation (ICH) S7B and updated E14/S7B Q&A 2.1 regulatory standards, evaluating concentration-dependent hERG current inhibition using standardized voltage-clamp electrophysiology is a mandatory component of core safety pharmacology testing before first-in-human clinical trials.
This page describes products and general use; it is not medical advice.
Definition and Electrophysiological Scope of the hERG Assay
The human Ether-à-go-go-Related Gene (hERG, designated KCNH2) encodes the pore-forming alpha subunit of the Kv11.1 voltage-gated potassium channel. In human cardiac physiology, Kv11.1 tetramers conduct the rapid delayed rectifier potassium current (IKr) in ventricular myocytes. This outward current is decisive during Phase 2 (plateau) and Phase 3 (repolarization) of the ventricular action potential, restoring negative resting membrane potential. Unintended inhibition of this current prolongs action potential duration, manifesting on electrocardiograms as prolongation of the corrected QT interval (QTc).
Nonclinical cardiac safety evaluation was formally standardized following major clinical drug withdrawals in the late 1990s and early 2000s—including terfenadine, cisapride, and sertindole—which caused acquired long QT syndrome and fatal arrhythmias through off-target hERG blockade. In response, regulators established ICH S7A and ICH S7B in 2005. Together with ICH M3(R2) nonclinical safety guidelines, these frameworks require sponsors to profile hERG liability in early hit-to-lead stages and furnish definitive in vitro electrophysiological data before initiating human clinical trials.
In drug discovery, the hERG assay operates at two key stages: high-throughput screening during lead optimization to establish structure-activity relationships (SAR) that weed out cardiac liabilities, and GLP-compliant whole-cell patch-clamp assays in preclinical development to calculate the half-maximal inhibitory concentration (IC50) for safety margin determination.
Electrophysiological Principles: Gating Kinetics and Standardized Voltage Protocols
Evaluating hERG block requires understanding Kv11.1 gating kinetics. Unlike classic shaker potassium channels, hERG exhibits slow activation upon depolarization combined with rapid, voltage-dependent C-type inactivation. At depolarized potentials (+20 mV to +40 mV), channels activate slowly but inactivate almost instantaneously into a non-conducting conformation, permitting minimal outward current. Upon membrane repolarization to negative voltages (-40 mV to -50 mV), channels recover from inactivation roughly ten to twenty times faster than they deactivate (close), generating a transient surge of outward current termed the hERG tail current.
Because the peak amplitude of this tail current reflects the population of functional, unblocked channels opened during depolarization, standardized voltage-clamp protocols measure tail current inhibition rather than step currents:
- Holding Potential: The membrane is clamped at -80 mV, matching ventricular resting potential and maintaining channels in a closed state.
- Depolarizing Step: Membrane voltage is stepped to +20 mV or +40 mV for 1.0 to 2.0 seconds, activating channels and rapidly driving them into inactivation.
- Repolarizing Step: Potential is stepped down to -50 mV for 1.0 to 2.0 seconds, allowing channels to transition through the open conducting state and generating peak outward tail current.
- Inter-Sweep Interval: Pulses repeat at a physiological frequency of 0.2 Hz (every 5 seconds) to allow channel recovery and prevent cumulative artifacts.
At the end of recording, 0.5 µM to 1.0 µM of the selective blocker E-4031 is applied to extinguish all Kv11.1 current. Subtracting this residual leak baseline from initial baseline and drug-exposed sweeps isolates pure hERG conductance.
Screening Technologies: Manual Patch Clamp, Automated Electrophysiology, and High-Throughput Assays
Drug discovery programs utilize multiple testing platforms, balancing throughput against physiological fidelity and regulatory acceptance.
The manual whole-cell patch-clamp (MPC) technique remains the gold standard in safety pharmacology. A micromanipulator positions a glass micropipette onto a mammalian cell (HEK293 or CHO cells stably expressing human KCNH2). Gentle suction achieves whole-cell access with true giga-ohm seals (>1 GΩ), electronic series resistance compensation (70% to 85%), and flexible perfusion. However, throughput is limited to 5 to 15 concentration-response curves per operator daily.
Planar automated patch clamp (APC) platforms—such as Sophion’s QPatch and Nanion’s SyncroPatch—overcame throughput bottlenecks using microfluidic chips with micro-machined apertures. Modern APC systems achieve giga-ohm seal rates exceeding 80%, automated series resistance tracking, and throughputs of 500 to 5,000 data points daily. Validation studies show APC platforms yield IC50 values closely concordant with manual patch clamp, with differences typically under three-fold.
For primary high-throughput screening (HTS), surrogate assays provide early triage:
- Thallium (Tl+) Flux Assays: Thallium acts as a potassium surrogate, permeating open hERG channels. Cells pre-loaded with thallium-sensitive dyes (such as FluxOR) emit fluorescence upon influx. Scalable to 384- and 1536-well formats, thallium assays frequently exhibit 10-fold to 100-fold potency shifts compared to voltage clamp due to non-physiological ion gradients.
- Fluorescence Polarization (FP) Binding Assays: FP assays (such as Predictor hERG) measure displacement of a fluorescent tracer from isolated membranes. Homogeneous and cell-free, FP measures competitive displacement at the central cavity but misses allosteric or state-dependent inhibition.
- Radioligand Binding Assays: Filter-binding assays using tritiated ligands ([3H]-dofetilide or [3H]-astemizole) quantify equilibrium displacement from membranes. While useful for static binding affinity (Ki), they involve radioactive waste and cannot assess use-dependent channel block.
The comparative performance attributes across these analytical modalities are summarized below:
| Platform Type | Primary Readout | Seal Quality | Voltage Control | Daily Throughput | Regulatory Status |
|---|---|---|---|---|---|
| Manual Patch Clamp | Direct ionic current (pA) | Giga-ohm (>1 GΩ) | Complete step-ramp control | 5–15 cells/day | Gold standard (ICH S7B / GLP) |
| Planar Automated Patch Clamp | Direct ionic current (pA) | Giga-ohm (>1 GΩ) | Automated step-ramp control | 500–5,000 data points/day | Accepted for nonclinical dossiers |
| Thallium Flux (FluxOR) | Fluorescence emission | None (cell ensemble) | Indirect (depolarizing buffer) | 10,000–50,000 wells/day | Early screening triage only |
| Fluorescence Polarization | Fluorescence anisotropy | Cell-free membrane | None (biochemical binding) | 5,000–20,000 wells/day | Early SAR triage only |
| Radioligand Binding | Radioactive counts (CPM) | Cell-free membrane | None (equilibrium binding) | 1,000–5,000 wells/day | Secondary binding confirmation |
ICH S7B Q&A 2.1 Best Practices: Temperature, Solution Chemistry, and Drug Loss
In 2022, the ICH adopted updated Questions and Answers (Q&As) for ICH S7B and E14. ICH S7B Q&A 2.1 delineates experimental best practices for in vitro patch-clamp studies to minimize inter-laboratory variability. Benchmarking by HESI and the US FDA demonstrated that compliance with Q&A 2.1 harmonizes data across testing facilities.
The core requirements under Q&A 2.1 cover five critical parameters:
1. Physiological Recording Temperature: Historically, hERG screens were often run at room temperature (20°C–25°C) to prolong seal stability. However, temperature significantly alters gating kinetics and drug-binding equilibria. Compounds like sotalol, E-4031, and terfenadine exhibit marked temperature-dependent potency shifts between room temperature and near-physiological body temperature (35°C–37°C). Under Q&A 2.1, definitive assays must be conducted at 35°C to 38°C, verified by an in-chamber thermistor.
2. Standardized Buffer Formulations: Inter-laboratory consistency requires controlled electrolyte composition and osmolarity:
- External Buffer: 130 mM NaCl, 5 mM KCl, 1 mM MgCl2·6H2O, 1 mM CaCl2·2H2O, 10 mM HEPES, and 12.5 mM dextrose (pH 7.4 with NaOH; ~280 mOsm/L).
- Internal Solution: 120 mM potassium gluconate, 20 mM KCl, 10 mM HEPES, 5 mM EGTA, and 1.5 mM MgATP (pH 7.3 with KOH; ~280 mOsm/L).
- Liquid Junction Potential: These solutions generate a 15 mV junction potential at the pipette tip, which must be mathematically corrected in voltage command protocols.
3. Analytical Exposure Verification and Perfusion Adsorption Loss: Compound loss from non-specific binding to perfusion lines and chambers is a primary cause of inaccurate IC50 values. Highly lipophilic compounds (LogP > 3.0) adsorb rapidly to fluidic plastics, reducing actual exposure at the cell by 30% to 80% compared to nominal concentrations. Q&A 2.1 recommends verifying chamber concentrations using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS), recalculating curves based on measured exposure.
4. Objective Cell Health Filters: Patch recordings must maintain seal resistance >1 GΩ, holding current under -100 pA at -80 mV, series resistance <15 MΩ with 70% to 85% compensation, and tail current run-down rates <5% per minute.
5. Reference Controls and Natural Variability: Assays must incorporate positive controls (such as dofetilide, cisapride, or terfenadine). Multi-laboratory studies show that natural biological and mechanical variability spans an approximate 5-fold distribution (~5X); potency values within 5X across facilities represent expected assay noise rather than true pharmacological differences.
From Redfern Margins to CiPA: Multichannel Integration and In Silico Modeling
For two decades, safety pharmacology evaluated hERG data using the provisional safety margin from Redfern et al. (2003), recommending that in vitro hERG IC50 be at least 30 times higher than free therapeutic clinical plasma concentration (Cmax, unbound):
Safety Margin Ratio = hERG IC50 / Free Cmax
While sensitive, this 30-fold threshold suffers from poor specificity, creating false-positive flags for safe drugs. Verapamil (calcium channel blocker) and ranolazine (antianginal) both block hERG at clinical concentrations with safety ratios well below 30 (verapamil ~1.8; ranolazine ~5.9), yet neither causes TdP clinically because both act as antiarrhythmics.
This occurs because ventricular repolarization balances outward currents (IKr via hERG, IKs via Kv7.1) and inward currents (ICa,L via Cav1.2, late INa,L via Nav1.5). Concurrently blocking hERG and inward calcium or late sodium currents offsets potassium conductance loss, suppressing early afterdepolarizations (EADs).
To establish a mechanistic paradigm, regulators introduced the Comprehensive in Vitro Proarrhythmia Assay (CiPA) four-pillar framework:
- Pillar 1: Multichannel Profiling: Evaluating candidates across cardiac channels (hERG, Cav1.2, Nav1.5 peak/late, Kv7.1, Kir2.1) to quantify binding kinetics and state-dependent block.
- Pillar 2: In Silico Modeling: Integrating in vitro parameters into biophysical human ventricular action potential simulations (such as O’Hara-Rudy models) to compute qNET (net repolarization charge).
- Pillar 3: Human iPSC Validation: Biologically verifying predictions using human induced pluripotent stem cell (iPSC) culture on multi-electrode arrays.
- Pillar 4: Integrated Clinical Assessment: Matching Phase 1 clinical ECG concentration-QTc modeling with nonclinical predictions. Under ICH E14 Q&As 5.1 and 6.1, a negative nonclinical CiPA profile meeting S7B Q&A 2.1 best practices can waive a dedicated Thorough QT study.
The structured data table below compares these multi-channel pharmacological parameters, calculated safety ratios, lipophilicity values, and measured fluidic line adsorption losses across benchmark reference drugs evaluated under standardized cardiac safety protocols.
Step-by-Step Assay Workflow and Quality Control Acceptance Criteria
Executing a GLP-compliant hERG patch-clamp study follows a structured operational workflow:
- Cell Culture and Harvesting: Recombinant HEK293 or CHO-K1 cells stably expressing human Kv11.1 are maintained at 37°C and 5% CO2 and passaged at 70% to 80% confluence per standard cell culture seeding densities and vessel parameters. Cells are gently dissociated using low-concentration enzymes, washed, and resuspended in recording buffer with cell viability >90%.
- Pipette Pulling and Fire-Polishing: Borosilicate glass capillary tubes are pulled and fire-polished to achieve tip resistances of 2.0 to 4.0 MΩ when filled with potassium gluconate internal solution. Positive pressure is maintained in the pipette during immersion.
- Gigaseal Formation and Whole-Cell Access: The pipette is lowered onto a cell. Upon membrane contact, pressure is released and gentle suction is applied until seal resistance exceeds 1.0 GΩ. Brief negative pressure ruptures the patch, achieving whole-cell electrical access.
- Electronic Compensation and Baseline Stabilization: The cell is clamped at -80 mV. Slow capacitive transients are cancelled, and series resistance is electronically compensated by 70% to 85%. The 0.2 Hz step-ramp protocol is applied with vehicle perfusion (0.1% DMSO) for 3 to 5 minutes until tail currents stabilize within 5% variation.
- Cumulative Test Article Perfusion: Test compounds prepared from DMSO stock solutions verified against manufacturer Certificate of Analysis (COA) verification documentation are perfused from lowest to highest concentrations (e.g., 0.01 µM to 100 µM) at 1.5 to 2.0 mL/min until steady-state inhibition is reached.
- Terminal Wash-In and Analysis: The cell is perfused with 1.0 µM E-4031 to abolish hERG current. Raw sweeps are leak-subtracted against this baseline and normalized to pre-drug amplitude. Data are fitted to the Hill equation to determine the IC50 and Hill coefficient.
Common Pitfalls, Measurement Artifacts, and Data Interpretation
Interpreting hERG safety data requires vigilance against recurring methodological artifacts:
- Uncorrected Liquid Junction Potentials: The 15 mV junction potential between gluconate internal and chloride external buffers shifts true membrane potential. Uncorrected amplifiers depolarize cells 15 mV less than command voltages, distorting activation kinetics.
- Adsorption Loss in Perfusion Lines: Lipophilic compounds (LogP > 3.5) bind to fluidic tubing, depleting dissolved drug before it reaches the cell. Failing to measure bath concentrations produces falsely elevated IC50 values that underestimate cardiac risk.
- Series Resistance Voltage Errors: Large hERG tail currents (2.0 to 4.0 nA) through uncompensated series resistance (Rs) introduce substantial voltage clamp errors (V = I × Rs). Quality standards require >=70% Rs compensation and discarding recordings where Rs exceeds 15 MΩ or drifts by >20%.
- Vehicle Run-Down: Dialysis of intracellular factors during whole-cell recordings can cause time-dependent current decline. Running parallel vehicle time controls distinguishes true pharmacological block from run-down.
- Aqueous Precipitation: Poorly soluble drugs at high concentrations (30 µM to 100 µM) can precipitate in aqueous buffer, causing irregular, sub-maximal inhibition curves that must be screened optically.
Frequently asked questions
What is the difference between manual and automated patch clamp in hERG testing?
Manual patch clamp uses individual glass micropipettes operated under a microscope, providing unmatched seal quality, flexible perfusion, and visual cell inspection, but yields only 5 to 15 data points daily. Automated patch clamp uses planar microfluidic chips containing micro-apertures where cell suspensions are positioned by suction, delivering high giga-ohm seal rates, automated fluidics, and throughputs of 500 to 5,000 data points daily. While manual patch clamp remains the formal gold standard under ICH S7B, automated systems are widely accepted for lead optimization and regulatory dossiers when verified against reference standards.
Why is hERG channel blockade specifically linked to Torsades de Pointes?
The hERG channel conducts the rapid delayed rectifier potassium current (IKr), the primary outward current terminating the cardiac action potential plateau. Blocking hERG delays ventricular repolarization, causing early afterdepolarizations (EADs) during Phase 2 and Phase 3 of the action potential. These cellular depolarizations can trigger polymorphic ventricular tachycardias known as Torsades de Pointes (TdP), which can degenerate into fatal ventricular fibrillation.
What is the Redfern 30-fold safety margin rule?
Formulated by Redfern et al. in 2003, the 30-fold safety margin rule states that a drug candidate’s in vitro hERG IC50 should be at least 30 times higher than its free (unbound) maximum therapeutic clinical plasma concentration (Cmax, unbound). While widely adopted as a nonclinical screening threshold, modern safety pharmacology recognizes that this ratio has high false-positive rates because it does not account for multichannel compensatory block, such as concurrent inhibition of inward calcium or late sodium currents.
How does the CiPA paradigm improve upon traditional hERG testing?
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) expands cardiac safety evaluation beyond single-target hERG screening by assessing drug effects across multiple human cardiac ion channels (hERG, Cav1.2, Nav1.5 peak and late, Kv7.1, Kir2.1). These multi-channel parameters are incorporated into in silico human ventricular action potential simulations to compute net repolarization charge (qNET) and validated in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), accurately identifying safe, multichannel-blocking drugs that would otherwise fail a simple hERG screen.
What causes compound loss during hERG electrophysiology experiments?
Compound loss occurs when lipophilic test molecules non-specifically adsorb to hydrophobic surfaces in laboratory fluidics, including glass reservoirs, fluoropolymer tubing, silicone tubing, and plastic perfusion chambers. For molecules with high lipophilicity (LogP greater than 3.0), non-specific binding can deplete 30% to 80% of the compound before it reaches the cell, resulting in artificially high measured IC50 values unless actual bath concentrations are analytically verified by LC-MS/MS.
Sources
- U.S. Food and Drug Administration and International Council for Harmonisation. (2022). E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential—Questions and Answers; Guidance for Industry. FDA-2020-D-1894. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-and-s7b-clinical-and-nonclinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic (Accessed 2026-11-15).
- Alvarez Baron, C., Zhao, J., Yu, H., Ren, M., Thiebaud, N., Guo, D., et al. (2025). Multi-laboratory comparisons of manual patch clamp hERG data generated using standardized protocols and following ICH S7B Q and A 2.1 best practices. Scientific Reports, 15(1), 29995. PMCID: PMC12357877. DOI: 10.1038/s41598-025-15761-8. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357877/ (Accessed 2026-11-15).
- Alvarez Baron, C., Thiebaud, N., Ren, M., Viatchenko-Karpinski, S., Indapurkar, A., et al. (2022). hERG block potencies for 5 positive control drugs obtained per ICH E14/S7B Q and As best practices: Impact of recording temperature and drug loss. Journal of Pharmacological and Toxicological Methods, 117, 107193. PMID: 35792285. DOI: 10.1016/j.vascn.2022.107193. URL: https://pubmed.ncbi.nlm.nih.gov/35792285/ (Accessed 2026-11-15).
- Crumb, W. J. Jr., Vicente, J., Johannesen, L., and Strauss, D. G. (2016). An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. Journal of Pharmacological and Toxicological Methods, 81, 251–262. PMID: 27060526. DOI: 10.1016/j.vascn.2016.03.009. URL: https://pubmed.ncbi.nlm.nih.gov/27060526/ (Accessed 2026-11-15).
- Kramer, J., Himmel, H. M., Lindqvist, A., Stoelzle-Feix, S., et al. (2020). Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in Recombinant cells. Scientific Reports, 10(1), 5627. PMCID: PMC7101356. DOI: 10.1038/s41598-020-62344-w. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101356/ (Accessed 2026-11-15).
- Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research, 58(1), 32–45. PMID: 12667944. DOI: 10.1016/s0008-6363(02)00846-5. URL: https://pubmed.ncbi.nlm.nih.gov/12667944/ (Accessed 2026-11-15).
Data: Standardized Cardiac Ion Channel Block Potencies, Safety Margins, and Perfusion Adsorption Loss for Reference Drugs
Compiled multi-laboratory benchmark dataset comparing in vitro hERG (IKr), late Nav1.5, and Cav1.2 inhibitory concentrations (IC50) with clinical free Cmax, Redfern safety margins, lipophilicity (LogP), and perfusion apparatus drug loss across eight reference pharmaceuticals evaluated under ICH S7B Q&A 2.1 and CiPA electrophysiology protocols.
Period covered: 2003/2025. Coverage: International.
| Compound | Clinical TdP Risk Category | Manual Patch Clamp hERG IC50 (nM) | Free Therapeutic Cmax (nM) | Safety Margin (hERG IC50 / Free Cmax) (ratio) | Late Nav1.5 IC50 (µM) | Cav1.2 IC50 (µM) | LogP (LogP) | Perfusion Apparatus Drug Loss (%) |
|---|---|---|---|---|---|---|---|---|
| Dofetilide | High | 12 | 2 | 6 | 100 | 100 | 1.3 | 8.5 |
| Cisapride | Intermediate | 10.1 | 4 | 2.5 | 32 | 25 | 3.4 | 54 |
| Terfenadine | Intermediate | 56 | 4 | 14 | 1.3 | 0.9 | 4.8 | 78 |
| Verapamil | Low | 143 | 81 | 1.8 | 15 | 0.2 | 3.8 | 42 |
| Ranolazine | Low | 11500 | 1940 | 5.9 | 5.9 | 50 | 1.8 | 12 |
| Sotalol | High | 124000 | 14700 | 8.4 | 300 | 300 | -0.8 | 3 |
| Quinidine | High | 550 | 870 | 0.63 | 16 | 14 | 2.9 | 28 |
| Diltiazem | Low | 17300 | 125 | 138.4 | 100 | 0.45 | 2.8 | 22 |
Sources
- Alvarez Baron et al. (2025) Multi-laboratory comparisons of manual patch clamp hERG data (accessed 2026-11-15)
- Alvarez Baron et al. (2022) hERG block potencies for 5 positive control drugs (accessed 2026-11-15)
- Crumb et al. (2016) An evaluation of 30 clinical drugs against the CiPA ion channel panel (accessed 2026-11-15)
- Redfern et al. (2003) Relationships between preclinical cardiac electrophysiology and torsade de pointes (accessed 2026-11-15)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







